The story is almost always the same. A red, bumpy rash appears on the face. It is diagnosed as eczema, or dermatitis, or “sensitive skin.” A topical steroid is prescribed. For about a week it works beautifully — the redness melts away and you think you have finally found the answer. Then you stop, and it comes back worse than before. So you use the cream again. And again. Each cycle, the rash returns angrier, and eventually a stronger steroid is prescribed.
If this is your story, there is a specific, well-documented explanation, and it is not that your skin is “steroid dependent.” The steroid was never treating the rash. It was feeding it.
Quick Answer
Immunosuppression — whether from medication, disease, or treatment — is one of the strongest drivers of Demodex overgrowth, and topical corticosteroids on the face are among the most common and most overlooked triggers. Demodex is normally held at low density by local immune surveillance. When that surveillance is suppressed, the mites proliferate, producing what is classified as secondary demodicosis. Documented triggers include topical and systemic corticosteroids, calcineurin inhibitors (tacrolimus, pimecrolimus), methotrexate, azathioprine, cyclosporine, biologic therapy, EGFR inhibitors, chemotherapy, and post-transplant regimens. Severe or crusted demodicosis is documented in advanced HIV/AIDS, haematologic malignancy, and stem cell and organ transplant recipients — where it can closely mimic graft-versus-host disease. The diagnostic threshold is five or more mites per cm² on standardized skin surface biopsy. The clinical tell: a facial rash that improves briefly on a steroid then rebounds worse each time you stop is Demodex until proven otherwise.
The Topical Steroid Trap
Under normal conditions, a dynamic balance exists between your immune system and your mite population. The mites are there, but the immune system keeps them in check without producing symptoms. Local immunosuppression — including from a cream you rub on your face — disrupts that balance directly.
Why it looks like it is working
Corticosteroids are powerful anti-inflammatories. When you apply one, it suppresses the inflammatory response your immune system is mounting against the mites. The redness fades. The bumps calm down. You experience this as the treatment working. But the mites themselves are entirely unharmed. In fact, the immune pressure holding them down has just been lifted, and they begin to multiply.
Why it gets worse when you stop
When you discontinue the steroid, the immune response returns — but now it is confronting a substantially larger mite population than it started with. The rebound is worse than the original rash, because the underlying cause has grown. The intuitive response is to reach for the cream again, or a stronger one. Each cycle deepens the problem.
This is steroid-induced (secondary) demodicosis, and it is thoroughly documented in the dermatology literature. Case reports describe patients managed for chronic pruritus with topical corticosteroids and no improvement, where prolonged steroid use was ultimately identified as having induced local immunosuppression that facilitated the mite proliferation causing the symptoms in the first place.
The single most useful diagnostic clue in this article
A facial rash that improves on a steroid, rebounds worse when you stop, and becomes progressively harder to control with each cycle is Demodex until proven otherwise. This pattern is not typical of true eczema. If you recognize it, ask specifically for Demodex testing — a standardized skin surface biopsy — before the steroid potency is escalated again.
Calcineurin inhibitors are not a safe alternative
Patients who develop steroid problems are frequently switched to a topical calcineurin inhibitor — tacrolimus or pimecrolimus — as a “steroid-sparing” option. Unfortunately, these are also immunosuppressants. Multiple case reports describe a rosacea-like facial eruption developing after both long- and short-term facial use of pimecrolimus and tacrolimus, with Demodex mites recovered in numbers meeting the diagnostic definition of demodicosis. Swapping one facial immunosuppressant for another does not break the cycle.
Who Is at Risk — Ranked by Severity
Highest risk — severe, crusted, or nodular demodicosis
- Advanced HIV/AIDS. Demodicosis has been described as an opportunistic skin infection in this population, with crusted and exuberant lesions reported, particularly in patients also on chronic steroids.
- Haematologic malignancy on chemotherapy. Leukemia and lymphoma patients receiving chemotherapy show markedly increased mite numbers. In one series, acute myelocytic leukemia patients on cytosine arabinoside, daunorubicin, hydroxyurea and mitozantrone had the highest recorded Demodex density.
- Paediatric acute lymphoblastic leukaemia. Demodicosis has been specifically described as an opportunistic skin infection in immunocompromised children receiving chemotherapy for ALL, presenting as a pruritic papulopustular facial eruption.
- Allogeneic stem cell transplant. Demodex folliculitis after stem cell transplant presents as facial erythematous papules that closely mimic acute graft-versus-host disease. Published cases describe a distinctive cutoff sign at the scalp — sparing of the scalp — that helps distinguish demodicosis from GVHD, viral exanthem, drug reaction, and chemotherapy toxicity.
- Solid organ transplant. Case series in kidney transplant recipients on mycophenolate mofetil, tacrolimus, and prednisone describe facial itching and burning with confirmed Demodex, requiring prolonged (multi-month) acaricidal therapy.
High risk — papulopustular or rosacea-like eruption
- Topical corticosteroids on the face (the most common trigger by volume)
- Calcineurin inhibitors: tacrolimus, pimecrolimus
- Systemic corticosteroids
- Methotrexate, azathioprine, cyclosporine
- Biologic therapy
- EGFR inhibitors (a documented trigger of demodicidosis)
Moderate risk — relative or metabolic immunosuppression
- Diabetes mellitus — see our dedicated guide on Demodex and diabetes
- End-stage renal disease
- PUVA and narrowband UVB phototherapy to the face (local immunosuppression plus sebaceous gland hypertrophy)
- Advancing age (prevalence approaches 100% over 70)
The Evidence: What Happens When You Start an Immunosuppressant
The cleanest prospective data comes from Keles and colleagues, published in Medicina in 2020. They measured Demodex density in 45 patients before and during immunosuppressive therapy for psoriasis vulgaris, pemphigus vulgaris, alopecia areata, or lichen planus — using methotrexate, cyclosporine, systemic steroids, or azathioprine — with 45 matched healthy controls, sampling by five standardized skin surface biopsies from cheeks, forehead, nose, and chin.
The Demodex test was negative in every patient at baseline. It then turned positive in patients during treatment, at both the first and third month timepoints, while the control group remained essentially static. The observation is straightforward: starting an immunosuppressant converted Demodex-negative patients into Demodex-positive patients within months.
A 2022 PRISMA-guided review of demodicosis among immunocompromised patients gathered 13 original works, 23 case reports, and 10 reviews, confirming the pattern across HIV, transplant, and autoimmune populations, and noting that treatment in this group is weakly evidence-based and typically requires prolonged courses.
How It Is Diagnosed
The diagnosis is made by microscopic analysis of skin scrapings or, preferably, standardized skin surface biopsy (SSSB) from the forehead, cheeks, nose, or chin. Five or more mites per cm² under light microscopy is considered a positive result.
The presentation is heterogeneous, which is why it is missed. Symptomatic demodicosis can appear as rosacea, pityriasis folliculorum, papulopustular eruptions, perioral dermatitis, or blepharitis. In immunosuppressed patients it may additionally present as crusted, granulomatous, nodular, or even cystic facial lesions — and, notably, as facial hyperpigmentation that can be mistaken for melasma or lichen planus pigmentosus.
Our guide on how to test for Demodex mites covers the SSSB technique in detail.
For Practitioners
Recognition and management:
- Make SSSB reflexive in any immunosuppressed patient with a facial eruption. The differential in this population (GVHD, drug eruption, viral exanthem, chemotherapy toxicity, folliculitis) rarely includes demodicosis, and it should. Threshold: ≥5 mites/cm².
- The scalp cutoff sign. In post-HSCT facial erythema, sparing of the scalp has been described as a discriminating feature favouring Demodex folliculitis over acute GVHD. Cheap, immediate, and clinically actionable.
- Interrogate the steroid history before escalating potency. The pattern of transient improvement followed by progressively worse rebound is the signature of steroid-induced secondary demodicosis. Escalating potency deepens the problem. Calcineurin inhibitors are not a safe substitute — they are also documented triggers.
- Anticipate prolonged courses. In transplant case series, two months of topical ivermectin plus permethrin still showed persistent Demodex; clinical improvement required a further two months. Standard 4–6 week courses are frequently inadequate in this population — counsel accordingly or the patient will self-discontinue.
- Consider demodicosis in facial hyperpigmentation on immunosuppressants. A documented and easily-missed presentation; dermoscopy plus anti-demodectic therapy has produced dramatic response in reported cases.
- Do not withdraw essential immunosuppression. The goal is to identify and treat the demodicosis, not to compromise the transplant, oncology, or autoimmune regimen. Where the trigger is a facial topical (steroid, calcineurin inhibitor) prescribed for a rash that is actually demodicosis, withdrawal of that specific agent alongside acaricidal therapy is appropriate.
- Screen for concurrent metabolic drivers. Diabetes and immunosuppression frequently co-occur (steroids raise glucose), compounding risk. See the companion piece on Demodex and diabetes.
- Expect die-off. High baseline mite burden in immunosuppressed patients means a more pronounced inflammatory flare on initiating acaricidal therapy. Pre-warn the patient.
If You Recognize Yourself in This
You do not need to stop a medication that is keeping you alive or keeping a serious disease in remission. That is not the point of this article.
The point is that if you are immunosuppressed and you have a persistent facial rash, Demodex belongs on the list of things being tested for — and in most cases it never is. Ask for a standardized skin surface biopsy. If you are on a facial steroid or calcineurin inhibitor for a rash that keeps rebounding worse, ask whether that cream might be the cause rather than the cure.
Our complete step-by-step treatment protocol covers the sequenced approach, and the die-off guide explains the flare you may experience in the first weeks of treatment.
Frequently Asked Questions
Can steroid cream cause Demodex?
Topical corticosteroids do not create Demodex mites — you already carry them — but they suppress the local immune surveillance that keeps mite density low, allowing overgrowth. This is called secondary or steroid-induced demodicosis and is well documented. It is one of the most common and most overlooked triggers.
Why does my face rash get worse when I stop the steroid cream?
Because the steroid suppressed your inflammatory response to the mites without killing the mites, which multiplied underneath. When you stop, your immune response returns and confronts a much larger mite population than before — so the rebound is worse than the original rash. Each cycle deepens the problem.
Is tacrolimus or pimecrolimus safer than steroids for Demodex?
No. Calcineurin inhibitors are also immunosuppressants, and multiple case reports describe a rosacea-like facial eruption with Demodex overgrowth after both short- and long-term facial use of pimecrolimus and tacrolimus. Switching from a steroid to a calcineurin inhibitor does not break the cycle.
Do chemotherapy patients get Demodex?
Yes. Leukemia and lymphoma patients receiving chemotherapy show markedly increased Demodex density, and demodicosis has been described as an opportunistic skin infection in children receiving chemotherapy for acute lymphoblastic leukaemia, typically as a pruritic papulopustular facial eruption.
Can Demodex be mistaken for graft-versus-host disease?
Yes, and this is clinically important. Demodex folliculitis after allogeneic stem cell transplant presents as facial erythematous papules that closely mimic acute GVHD. Published cases describe a distinctive sparing of the scalp — a “cutoff sign” — that helps distinguish demodicosis from GVHD and other causes of post-transplant facial erythema.
How is Demodex diagnosed in immunosuppressed patients?
By microscopic examination of skin scrapings or, preferably, standardized skin surface biopsy (SSSB) from the forehead, cheeks, nose, or chin. Five or more mites per cm² is considered a positive result. In any immunosuppressed patient with an unexplained facial eruption, this test should be routine.
Should I stop my immunosuppressant if I have Demodex?
Not on your own, and generally not at all if it is treating a serious condition. The goal is to identify and treat the demodicosis while keeping essential therapy in place — which usually means a longer acaricidal course than a healthy patient would need. The exception is a facial steroid or calcineurin inhibitor prescribed for a rash that is actually demodicosis; that specific agent may be perpetuating the problem. Discuss with your prescribing clinician.
How long does Demodex treatment take in immunosuppressed patients?
Longer than standard. In transplant case series, two months of combined topical ivermectin and permethrin still showed persistent Demodex, with clinical improvement only after a further two months. Expect prolonged courses and plan a maintenance phase.
Further Reading
- Demodex and Diabetes — the metabolic driver of overgrowth
- How to Test for Demodex Mites — the SSSB technique
- The Complete Step-by-Step Demodex Treatment Protocol
- Ivermectin for Demodex
- The Demodex Die-Off Reaction
- Perioral Dermatitis and Demodex — another steroid-linked presentation
- Demodex and Rosacea: The Clinical Guide
- Natural Remedies for Demodex: A Clinical Evidence Review
- Demodex Research Hub
References
- Keles H, Pancar Yuksel E, Aydin F, Senturk N. Pre-Treatment and Post-Treatment Demodex Densities in Patients under Immunosuppressive Treatments. Medicina (Kaunas). 2020;56(3):107. doi:10.3390/medicina56030107 Link
- Demodicosis among immunocompromised patients: a review. 2022. (PRISMA-guided; 13 original works, 23 case reports, 10 reviews) Link
- Sparing of the scalp in severe Demodex folliculitis after stem cell transplantation. JAAD Case Rep. 2018. Link
- Marquardt-Feszler A, Cekala K, Debska-Slizien A, Imko-Walczuk B. Demodicosis as a Skin Complication in Organ Transplant Recipients: A Case Series. Am J Case Rep. 2022. Link
- Gazi U, Taylan-Ozkan A, Mumcuoglu KY. Immune mechanisms in human and canine demodicosis: A review. Parasite Immunol. 2019;41(12):e12673. doi:10.1111/pim.12673 Link
- Diagnostic Challenges of Demodicosis in a 65-Year-Old Man: A Case of Chronic Pruritus. 2025. Link
- Seyhan ME, Karincaoglu Y, Bayram N, Aycan O, Kuku I. Density of Demodex folliculorum in haematological malignancies. J Int Med Res. 2004;32(4):411-415. Link
- Akilov OE, Mumcuoglu KY. Immune response in demodicosis. J Eur Acad Dermatol Venereol. 2004;18(4):440-444. doi:10.1111/j.1468-3083.2004.00964.x Link
- Chen W, Plewig G. Human demodicosis: revisit and a proposed classification. Br J Dermatol. 2014;170(6):1219-1225. Link
- Amal El-Sayed M, et al. Raising awareness of Demodex mites: a neglected cause of skin disease. Infection. 2025;53(4):1273-1298. doi:10.1007/s15010-025-02521-z Link